Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04682548 · ClinicalTrials.gov registry record
Estimating Prevalence of COVID-19 Infection and SARS-CoV-2 Antibodies in MS Patients
A clinical trial, sponsored by NYU Langone Health.
- Completed
- Registry status
- 920
- Enrollment target
NCT04682548 is a clinical trial that has completed, run by NYU Langone Health. The registered enrollment target is 920 participants.
The verdict
NCT04682548 has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- 920 participants
- Enrollment target
Study Summary
This non-interventional, biospecimen collection study is designed to help us better understand whether MS patients have impaired immune defenses to COVID-19 infection. The potential influence of immune modulating medications for MS will be considered through these exploratory studies. This study is also designed to provide context for interpretation of anti-SARS CoV2 serologies in MS patients during convalescence from COVID-19 infection.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 920 participants |
| Start Date | 2021-01-05 |
| Est. Completion | 2022-09-15 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04682548
The ClinicalTrials.gov registry entry for NCT04682548 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 920 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT04682548 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04682548 about?
NCT04682548 is a clinical study titled "Estimating Prevalence of COVID-19 Infection and SARS-CoV-2 Antibodies in MS Patients". This non-interventional, biospecimen collection study is designed to help us better understand whether MS patients have impaired immune defenses to COVID-19 infection. The potential influence of immune modulating medications for MS will be considered through these exploratory studies. This study is ...
What is the current status of trial NCT04682548?
This trial is currently completed. The enrollment target is 920 participants. The study started on 2021-01-05. Estimated completion is 2022-09-15.
Who is sponsoring clinical trial NCT04682548?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.